NOW FDA
APPROVED

SYMBRAVO
The power to deliver rapid, lasting migraine relief¹

SYMBRAVO provided rapid freedom from migraine pain and most bothersome symptom^a at 2 hours and lasting pain freedom through 24 hours for some patients.

AVAILABLE IN THE COMING MONTHS

Stay Informed

For patients who aren't getting the relief they need, discover SYMBRAVO¹

SYMBRAVO is a new 1-tablet medication for the acute treatment of migraine with or without aura in adults.¹ It offers a new option for migraine sufferers, including those who had inadequate response to prior acute migraine treatments.²

What makes SYMBRAVO different is MoSEIC™ absorption-accelerating technology combined with meloxicam and rizatriptan.^1,3 The absorption of both active ingredients was shown to be accelerated in this patented formulation.^1,4

The clinical significance of MoSEIC™ pharmacokinetic impact on the active ingredients in SYMBRAVO has not been established; it is not known precisely how MoSEIC™ technology works to accelerate the absorption of rizatriptan.

Across 2 controlled trials,
SYMBRAVO delivered powerful results¹:

Rapid freedom from migraine pain^b and MBS (coprimary endpoints)^a

Chart with INTERCEPT coprimary endpoints.

Chart with MOMENTUM coprimary endpoints.

Significantly greater percentage of patients experienced sustained pain freedom vs rizatriptan

In the MOMENTUM trial (N=1594), 16.1% of patients taking SYMBRAVO experienced sustained pain freedom through 24 hours vs 11.2% with rizatriptan (P=0.038, secondary endpoint).^1,d,e

Generally well tolerated with an established safety profile

Across 2 controlled trials and a 12-month open-label extension study, SYMBRAVO was generally well tolerated with a safety profile consistent with its individual components.^1,5 The most common adverse events in controlled trials were somnolence (2%) and dizziness (2%).¹

Resources

Download these resources
to learn more about SYMBRAVO.

Press Release

Prescribing Information

Medication Guide

Sign up to speak with a Rep and to receive more information.

FDA-approved SYMBRAVO will be available in the coming months.

*Required fields

First Name*

First name required

Last Name*

Last name required

Email Address*

Valid email address required

Phone Number

Enter valid phone #

NPI #*

Valid NPI # required

Specialty*

Specialty required

Check box to be contacted by an Axsome representative.

By checking this box you confirm that you are a US healthcare professional and that you have read and understand the Privacy Policy and Terms of Use. You are indicating that you would like to receive information from Axsome Therapeutics, Inc., about educational programs, products, and services. You can opt out at any time.

User agreement is required

^a: MBS freedom was defined as the absence of the self-identified MBS (ie, photophobia, phonophobia, or nausea).¹

^b: Pain freedom was defined as a reduction to no headache pain.¹

^c: INTERCEPT was a randomized, double-blind, controlled trial in 302 patients with a history of migraine, with or without aura in which patients took a single dose of SYMBRAVO.¹ Efficacy analysis was performed on the intent-to-treat (ITT) population, which included all patients who were randomized and had a qualifying migraine event (267 adult patients: SYMBRAVO, N=132; placebo, N=135). P-values were based on chi-squared test. Missing data were not imputed.²

^d: MOMENTUM was a randomized, double-blind, controlled trial in 1594 patients [SYMBRAVO (N=456), 10-mg rizatriptan (N=456), 20-mg meloxicam (N=455), placebo (N=227)] with a history of migraine with or without aura in which patients took a single dose of SYMBRAVO.¹ Efficacy analysis was performed on the intent-to-treat population (1477 adult patients with migraine: SYMBRAVO, N=428; rizatriptan, N=419; meloxicam, N=421; placebo, N=209). P-values were based on chi-squared test. Missing data were not imputed.²

^e: Patients who did not meet all the following requirements were considered nonresponders: pain intensity at and between hours 2 and 24 was 0; pain intensity was available for at least hour 12 or 16; and no rescue medication was used through hour 24.²

IMPORTANT SAFETY INFORMATION

INDICATION

SYMBRAVO is indicated for the acute treatment of migraine with or without aura in adults.

Limitations of Use:

SYMBRAVO should only be used when a clear diagnosis of migraine has been established. If a patient has no response for the first migraine attack treated with SYMBRAVO, the diagnosis of migraine should be reconsidered before SYMBRAVO is administered to treat any subsequent attacks.
SYMBRAVO is not indicated for the preventive treatment of migraine attacks.
SYMBRAVO is not indicated for the treatment of cluster headache.

WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS

Cardiovascular Risk

Non-steroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction, and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use.
SYMBRAVO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery.

Gastrointestinal Risk

NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events.

DOSAGE AND ADMINISTRATION

The recommended dose of SYMBRAVO is one tablet as needed for the acute treatment of migraine. The maximum daily dose should not exceed one tablet. The safety and effectiveness of a second dose for the same migraine attack have not been established. The safety of treating, on average, more than 7 headaches in a 30-day period has not been established. Use for the shortest duration consistent with individual patient treatment goals.

CONTRAINDICATIONS

Ischemic coronary artery disease (CAD), coronary artery vasospasm including Prinzmetal’s angina, or other significant underlying cardiovascular disease
In the setting of CABG surgery
History of stroke or transient ischemic attack (TIA)
Hemiplegic or basilar migraine
Peripheral vascular disease
Ischemic bowel disease
Uncontrolled hypertension
Concomitant use of propranolol

Recent (within 24 hours) use of another triptan, ergotamine containing medication, or ergot-type medication
Concurrent administration, or recent discontinuation (within 2 weeks), of a MAO-A inhibitor
Known hypersensitivity to meloxicam, rizatriptan, NSAIDs, SYMBRAVO, or any of its excipients
History of asthma, urticaria, or other allergic-type reactions after taking aspirin or NSAIDs: Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported
Patients with moderate to severe renal insufficiency at risk for renal failure due to volume depletion or who are on dialysis

WARNINGS AND PRECAUTIONS

Cardiovascular Thrombotic Events and Myocardial Infarction

: Avoid the use of SYMBRAVO in patients with a recent MI unless the benefits are expected to outweigh the risk of recurrent CV thrombotic events. If SYMBRAVO is used in patients with a recent MI, monitor patients for signs of cardiac ischemia. Perform a cardiovascular evaluation in triptan-naive patients with multiple cardiovascular risk factors and if satisfactory, consider administering the first dose in a medically supervised setting.

GI Bleeding, Ulceration, & Perforation

: NSAIDs, including meloxicam, a component of SYMBRAVO, can cause serious GI adverse events including inflammation, bleeding, ulceration, and perforation of the esophagus, stomach, small intestine, or large intestine, which can be fatal. These serious adverse events can occur at any time, with or without warning symptoms, in patients treated with meloxicam.

Arrhythmias

: Life-threatening arrhythmias, including ventricular tachycardia and ventricular fibrillation leading to death, have been reported within a few hours following the administration of 5-HT1 agonists. Discontinue SYMBRAVO if these arrhythmias occur.

Cerebrovascular Events

: Cerebral hemorrhage, subarachnoid hemorrhage, and stroke have occurred in patients treated with 5‑HT1 agonists, some resulting in fatalities. Discontinue SYMBRAVO if any of these events occur.

Before treating headaches in patients not previously diagnosed with migraine, and in patients with migraine who present with atypical symptoms, care should be taken to exclude other potentially serious neurological conditions.

Anaphylactic Reactions

: SYMBRAVO can cause anaphylactic reactions in patients with and without known hypersensitivity to meloxicam and in patients with aspirin-sensitive asthma. Hypersensitivity reactions, including angioedema and anaphylaxis, have also occurred in patients receiving rizatriptan. Seek emergency help if an anaphylactic reaction occurs.

Chest/Throat/Neck/Jaw Pain/Tightness, Pressure, or Heaviness

: Sensations of tightness, pain, pressure in the chest, and heaviness in the precordium, throat, neck, and jaw commonly occur after treatment with SYMBRAVO and are usually non-cardiac in origin. Perform a cardiac evaluation if a cardiac origin is suspected.

Other Vasospasm Reactions

: SYMBRAVO may cause non-coronary vasospastic reactions, such as peripheral vascular ischemia, gastrointestinal vascular ischemia and infarction, splenic infarction, and Raynaud’s syndrome. Discontinue SYMBRAVO if any of these events occur.

Reports of transient and permanent blindness and significant partial vision loss have been reported with the use of 5-HT1 agonists.

Hepatotoxicity

: Elevations of ALT or AST have been reported in patients taking NSAIDs. Rare, sometimes fatal cases of severe hepatic injury, including fulminant hepatitis, liver necrosis, and hepatic failure have been reported. Inform patients of the warning signs and symptoms of hepatotoxicity. Discontinue immediately if clinical signs and symptoms consistent with liver disease develop and perform a clinical evaluation.

Hypertension/Increase in Blood Pressure (BP)

: NSAIDs, including meloxicam, a component of SYMBRAVO, can lead to new onset of hypertension or worsening of pre-existing hypertension, either of which may contribute to the increased incidence of CV events. Patients taking angiotensin converting enzyme (ACE) inhibitors, thiazides or loop diuretics may have impaired response to these therapies when taking NSAIDs.

Significant elevation in BP, including hypertensive crisis with acute impairment of organ systems, has been reported on rare occasions in patients with and without a history of hypertension receiving 5-HT1 agonists, including rizatriptan, a component of SYMBRAVO.

Monitor BP during the initiation of the treatment and throughout the course of therapy.

Heart Failure and Edema

: Avoid the use of SYMBRAVO in patients with severe heart failure unless the benefits are expected to outweigh the risk of worsening heart failure. If SYMBRAVO is used in patients with severe heart failure, monitor patients for signs of worsening heart failure.

Renal Toxicity and Hyperkalemia

:
Renal Toxicity - Long-term administration of NSAIDs has resulted in serious renal injury, including acute renal failure. SYMBRAVO is not recommended in patients with moderate to severe renal insufficiency and is contraindicated in patients with moderate to severe renal insufficiency who are at risk for renal failure due to volume depletion. The renal effects may hasten the progression of renal dysfunction in patients with pre-existing renal disease.

Correct volume status in dehydrated or hypovolemic patients prior to initiating SYMBRAVO. Monitor renal function in patients with renal or hepatic impairment, heart failure, dehydration, or hypovolemia during use. Avoid the use in patients with advanced renal disease unless the benefits are expected to outweigh the risk of worsening renal function. If SYMBRAVO is used in patients with advanced renal disease, monitor patients for signs of worsening renal function.

Hyperkalemia - Increases in serum potassium concentration, including hyperkalemia, have been reported with use of NSAIDs, even in some patients without renal impairment.

Serious Skin Reactions

: NSAIDs, including SYMBRAVO, can cause serious skin adverse events such as exfoliative dermatitis, Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. NSAIDs can also cause fixed drug eruption (FDE). FDE may present as a more severe variant known as generalized bullous fixed drug eruption (GBFDE), which can be life-threatening. These serious events may occur without warning. Discontinue SYMBRAVO at the first appearance of skin rash or any other sign of hypersensitivity.

Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS)

: DRESS has been reported in patients taking NSAIDs, such as SYMBRAVO. Some of these events have been fatal or life-threatening. If signs or symptoms of DRESS are present, discontinue SYMBRAVO and evaluate the patient immediately.

Fetal Toxicity

: Limit use of NSAIDs, including SYMBRAVO, between about 20 to 30 weeks in pregnancy due to the risk of oligohydramnios/fetal renal dysfunction. Avoid use of NSAIDs in women at about 30 weeks gestation and later in pregnancy due to the risks of oligohydramnios/fetal renal dysfunction and premature closure of the fetal ductus arteriosus.

Hematologic Toxicity

: Anemia has occurred in NSAID-treated patients. Monitor hemoglobin or hematocrit in patients with any signs or symptoms of anemia. NSAIDs, including SYMBRAVO, may increase the risk of bleeding events. Monitor patients for signs of bleeding.

Exacerbation of Asthma Related to Aspirin Sensitivity

: In patients with preexisting asthma (without known aspirin sensitivity), monitor patients for changes in the signs and symptoms of asthma.

Medication Overuse Headache

: Overuse of acute migraine drugs may lead to exacerbation of headache. Detoxification and treatment of withdrawal may be necessary.

Serotonin Syndrome

: Serotonin syndrome may occur with triptans, including SYMBRAVO, particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants, and MAOIs. Discontinue SYMBRAVO if serotonin syndrome is suspected.

Masking of Inflammation and Fever

: The pharmacological activity of SYMBRAVO in reducing inflammation, and possibly fever, may diminish the utility of diagnostic signs in detecting infections.

Laboratory Monitoring

: Because serious GI bleeding, hepatotoxicity, and renal injury can occur without warning symptoms or signs, consider monitoring patients on long-term NSAID treatment with a CBC and a chemistry profile periodically.

DRUG INTERACTIONS

Monitor patients for bleeding who are concomitantly taking drugs that interfere with hemostasis. Analgesic doses of aspirin are not recommended.
Monitor blood pressure in patients taking ACE inhibitors, ARBs, or beta-blockers due to decreased antihypertensive effects.
Monitor for deterioration of renal function in elderly patients with renal impairment or volume depletion taking ACE inhibitors or ARBs.
Monitor for reduced diuretic efficacy in patients taking furosemide or thiazide diuretics.
Monitor lithium levels.
Monitor methotrexate levels.

USE IN SPECIFIC POPULATIONS: NSAIDs are associated with reversible infertility. Consider withdrawal of SYMBRAVO in women who have difficulties conceiving or who are undergoing investigation of infertility.

ADVERSE REACTIONS

Most common (≥1% and greater than placebo) adverse reactions after a single dose pooled from 2 studies were somnolence (2%) and dizziness (2%).

SYM HCP ISI 03/2025

Please see full Prescribing Information, including Boxed Warning, for risk of serious cardiovascular and gastrointestinal events.

REFERENCES

1. SYMBRAVO [prescribing information]. New York, NY: Axsome Therapeutics, Inc.; 2025. 2. Data on file. Axsome Therapeutics, Inc. 3. Tepper S, Lipton RB, Chhabra A, Streicher C, Parks G, Tabuteau H. Combined efficacy and safety of AXS-07 (MoSEIC™ meloxicam and rizatriptan) in two phase 3 clinical trials. Poster presented at: 76th American Academy of Neurology (AAN) Annual Meeting, April 13–18, 2024. 4. O’Gorman C, Jones A, TenHuisen K, et al. AXS-07 (MoSEIC™ meloxicam/rizatriptan): novel oral therapeutic in clinical development for the acute treatment of migraine. Presented at: 19th International Headache Society Congress, September 5–8, 2019. 5. Jones A, O’Gorman C, Tabuteau H. Treatment of migraine pain and associated symptoms with AXS-07: results from MOVEMENT, a long-term efficacy and safety study. Presented at: 63rd American Headache Society (AHS) Annual Scientific Meeting; June 3–6, 2021.

NOW FDAAPPROVED

SYMBRAVOThe power to deliver rapid, lasting migraine relief 1

For patients who aren't getting the relief they need, discover SYMBRAVO1

Across 2 controlled trials, SYMBRAVO delivered powerful results1:

Rapid freedom from migraine painb and MBS (coprimary endpoints)a